Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

EQL Pharma

52.30 SEK

-2.43 %

Less than 1K followers

EQL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Quarter data

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for EQL Pharma

Q1/25Q2/25Q3/25Q4/252025Q1/26Q2/26Q3/26
Revenue82.885.392.2113.3373.5107.286.4118.9
EBITDA15.214.314.823.067.420.58.924.9
EBIT15.214.314.823.067.420.53.619.5
EBIT-%18.4 %16.8 %16.1 %20.3 %18.0 %19.1 %4.2 %16.4 %
Profit before taxes13.112.112.716.554.412.4-4.212.3
Net income10.49.610.113.143.19.8-3.49.8
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.